Analysis

'On Sale' Ruling Shows Need For Earlier Patent Applications

Law360 (January 22, 2019, 9:07 PM EST) -- The U.S. Supreme Court’s decision not to revive a Helsinn patent on the nausea drug Aloxi has clarified the scope of the on-sale bar under the America Invents Act and underscored the need for inventors to file their patent applications as early as possible.

The U.S. Supreme Court decided not to revive Helsinn’s patent on its nausea drug Aloxi on Tuesday, clarifying the scope of the on-sale bar under the America Invents Act. (AP) In a unanimous ruling, the justices affirmed a Federal Circuit decision finding that the patent for Aloxi was invalid based on license and purchase agreements that Helsinn Healthcare SA...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!